Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitroCYP2D6 genotype and tamoxifen response.Clinical significance of the cytochrome P450 2C19 genetic polymorphismEndothelial nitric oxide synthase haplotypes are related to blood pressure elevation, but not to resistance to antihypertensive drug therapyCYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomesLiterature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactionsA genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in JapaneseCypiripi: exact genotyping of CYP2D6 using high-throughput sequencing data.Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing.Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapy.Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin.Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.PharmGKB summary: tamoxifen pathway, pharmacokineticsPharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics.A modulated empirical Bayes model for identifying topological and temporal estrogen receptor α regulatory networks in breast cancer.Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.Methadone: a substrate and mechanism-based inhibitor of CYP19 (aromatase).Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents.Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.Inhibition of cytochrome p450 enzymes by the e- and z-isomers of norendoxifen.CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.Substantial effect of efavirenz monotherapy on bilirubin levels in healthy volunteers.In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.In vitro cytochrome P450-mediated metabolism of exemestane.Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activitiesPharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.An integrated pharmacokinetics ontology and corpus for text mining.The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors.Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease.Morbid obesity and metabolic syndrome in Ossabaw miniature swine are associated with increased platelet reactivity.Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole.Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.Report of new haplotype for ABCC2 gene: rs17222723 and rs8187718 in cisGenotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials.Differential quantification of CYP2D6 gene copy number by four different quantitative real-time PCR assays
P50
Q24301858-49F2C7A4-B3FE-4ECB-81DF-22AC8ADBF61BQ24813762-62D38ACB-BD0C-402B-A297-080973B74758Q28201086-AB09E263-3245-4439-9820-792D5EB70AA1Q28272117-D12017B2-3D41-4013-884F-7ED4215932EEQ28277878-C9AD4764-AD76-44D1-9CA5-5604BE6737E9Q28482155-C72CAB67-A312-40EB-8785-24D1BC144A9FQ28943542-74FE80EA-4DD0-421E-942A-49C6EFDEA6A0Q30971296-06BDFAC4-F560-4DB9-A3E5-1401E3A160CCQ31110714-D4239ACD-40C9-4437-AA89-3A6496C705D5Q33635760-F7E2FEBE-471B-4CF5-83F5-8E8F6F86A56AQ33637840-DF4664C8-DDF2-41A8-8DCD-24E43A4ED711Q33793932-9DB12074-5446-4626-A046-40876A57535AQ33855494-5CA4FD6D-732C-45F6-A087-4D30D21DE285Q33855506-4ED86A3A-B35A-4D66-A152-61F9921A1C9AQ33893362-63F64E6F-1B82-432F-8074-C6D1DDB5E667Q34020925-7AE26AAA-39A9-46DC-82E5-988D10FA4B8AQ34034583-6A5503E3-9EAB-4F35-B5C5-6A63A8821680Q34065310-A760C442-2324-4831-BBFB-164DA33E97C1Q34205869-CDCB287F-52D0-4C86-997E-0086EE9A0210Q34315833-96627D6F-D1D0-429D-BCB0-DB8E5E5F3487Q34322613-58DBEBB8-4F18-4CEB-A5DA-2C90B2050921Q34355283-5B2BD94C-D2E1-4CE9-80EE-1978A2D38967Q34381754-658842C0-CB02-45C3-8797-C8C90EE65429Q34404878-7F6D762F-B2EC-4364-A072-1C1FA2855590Q34457429-F94CAF0B-54BC-4309-91D9-558222C322E4Q34458387-D00CBEC8-D510-4B09-88D7-351B7E99E18AQ34466243-6B6B9760-DBDE-460F-8603-42FF51F3E580Q34477526-47ACF41A-2C01-462F-944D-43C3B435A36BQ34488758-8D0FB087-1F71-4F5C-88F8-50DF116BA251Q34572334-377B7A38-3D4A-4982-B96F-C03323433A2FQ34653100-237C2131-5C4B-442C-BE05-CF1AB50BD9D1Q34847405-D2A8C1F3-E8AD-40F3-B04E-49ACBC747133Q34969512-817E8814-8E54-41C1-AFB3-B4ACFBACBC72Q35023196-4F340E50-A998-4C61-A3E9-BBD377A8CFB7Q35118969-A0502D15-785B-41C7-8F37-ACEC0C5E6BCBQ35126153-90DFE247-D7A5-44A6-8101-01897181A877Q35143783-0D7ECFCD-E571-422C-B6CC-F88B171DDD2FQ35172199-CAED5A76-EF8C-42C4-A872-5A96194ABBDEQ35510803-8AC59111-6B25-47EC-8576-994FF3E0DC97Q35545287-3F67C9CD-7AAA-4F1C-ADF6-3A4B53BECE9A
P50
name
David Flockhart
@ast
David Flockhart
@ca
David Flockhart
@en
David Flockhart
@es
David Flockhart
@fr
David Flockhart
@nl
David Flockhart
@sl
type
label
David Flockhart
@ast
David Flockhart
@ca
David Flockhart
@en
David Flockhart
@es
David Flockhart
@fr
David Flockhart
@nl
David Flockhart
@sl
prefLabel
David Flockhart
@ast
David Flockhart
@ca
David Flockhart
@en
David Flockhart
@es
David Flockhart
@fr
David Flockhart
@nl
David Flockhart
@sl
P21
P31
P373
David Flockhart
P569
1952-01-01T00:00:00Z
P570
2015-01-01T00:00:00Z